HC Wainwright & Co. Initiates Coverage On Kyverna Therapeutics With Neutral Rating, Announces Price Target of $8
HC Wainwright & Co. Initiates Coverage On Kyverna Therapeutics With Neutral Rating, Announces Price Target of $8
HC Wainwright公司宣佈,對Kyverna Therapeutics進行中立評級,並公佈8美元的目標價格。
HC Wainwright & Co. analyst Mitchell Kapoor initiates coverage on Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral rating and announces Price Target of $8.
HC Wainwright & Co.分析師米切爾.卡普爾以中立評級開始對Kyverna Therapeutics (納斯達克:KYTX) 的覆蓋並宣佈目標價格爲8美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。